Document is current

Article History

Received: 30 December 2024

Accepted: 21 April 2025

First Online: 16 June 2025

Declarations

:

: Not applicable.

: No individual patient data was collected. Not applicable.

: We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. None of the authors have conflicts of interests to disclose related to this review1.

: FEJ has served as consultant/advisor for UCB, GW Pharma (now Jazz Pharmaceuticals), and Novartis for which remuneration was made to the department, outside of the submitted work. JHC has received research grants from Zogenix (now a part of UCB), Marinus, GW Pharma (now Jazz Pharmaceuticals), Vitaflo, Stoke Therapeutics, Ultragenyx, National Institute of Health Research (NIHR), EPSRC, GOSH Charity, ERUK, the Waterloo Foundation, and the Great Ormond Street Hospital NIHR Biomedical Research Centre; and has served as consultant/advisor for Zogenix (now a part of UCB), GW Pharma (now Jazz Pharmaceuticals), and Biocodex for which remuneration was made to the department, outside of the submitted work; serves as Chair of the Medical Board for DravetUK, Hope for Hypothalamic Hamartoma, and Matthew’s Friends and endowed chair at UCL Great Ormond Street Institute of Child Health. EP received speaker’s or consultancy fees from Eisai, GRIN Therapeutics, SKI Life Science, Sintetica, SKL Life Science, Sun Pharma, Takeda, Xenon Pharmaceuticals, and royalties from Wiley, Elsevier, and Wolters Kluwers, all outside the submitted work. FO has received speaker or consultancy fees from Eisai, UCB Biopharma, GW Pharma (now Jazz Pharmaceuticals), and Novartis. VDG received a consultancy fee from Nutricia Gmbh. KPJB, VMD, EHB, WMO, and GJMWvT, have no disclosures to report.